<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Vesikari, Timo</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Effectiveness of the 10-Valent Pneumococcal NTHi Protein D Conjugate Vaccine against AOM</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-17</style></pages><abstract><style  face="normal" font="default" size="100%">Acute otitis media (AOM) is a common medical condition with high incidence in children &lt;5 years of age [Monasta L et al. PLoS One 2012]. Accurate diagnosis is difficult and may partially explain differences in incidence rates in different studies and countries [Toll EC, Nunez DA. J Laryngol Otol 2012]. A trial with the 11-valent predecessor protein D conjugate vaccine demonstrated efficacy against AOM episodes caused by S. pneumoniae and NTHi [Prymula R et al. Lancet 2006]. This article presents preliminary data showing a trend toward positive vaccine effectiveness against AOM episodes for 10-valent pneumococcal nontypeable H. influenzae protein D conjugate vaccine in infants.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>